PhospholipaseA2: A key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1761, Issue 11, 2006, Pages 1309-1316

  Oestvang, Janne ^a   Johansen, Berit ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Atherosclerosis; ECM; Inflammation; LDL; Lysophosphatidylcholine; PLA2

Indexed keywords

COLLAGEN; FATTY ACID; LIPID; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; SECRETORY PROTEIN; GROUP II SECRETORY PHOSPHOLIPASE A2; ICOSANOID; LYSOPHOSPHOLIPID; PHOSPHOLIPASE A;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL ADHESION; CELL GROWTH; CELLULAR DISTRIBUTION; CHEMOTAXIS; CHRONIC INFLAMMATION; COLLAGEN METABOLISM; COMPLEX FORMATION; ENZYME REGULATION; FOAM CELL; HUMAN; LIPID METABOLISM; MACROPHAGE; MACROPHAGE ACTIVATION; MEDIATOR; MITOGENESIS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR FIBROSIS; ANIMAL; CHRONIC DISEASE; ENZYMOLOGY; FIBROSIS; INFLAMMATION; INTIMA; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; CHRONIC DISEASE; COLLAGEN; EICOSANOIDS; FIBROSIS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MACROPHAGE ACTIVATION; MACROPHAGES; PHOSPHOLIPASES A; SIGNAL TRANSDUCTION; TUNICA INTIMA;

EID: 33750941731     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2006.06.003     Document Type: Review

References (68)

1. Balsinde J., Winstead M.V., and Dennis E.A. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett. 531 1 (2002) 2-6
2. Murakami M., Shimbara S., Kambe T., Kuwata H., Winstead M.V., Tischfield J.A., and Kudo I. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 273 23 (1998) 14411-14423
3. Elinder L.S., Dumitrescu A., Larsson P., Hedin U., Frostegard J., and Claesson H.E. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17 10 (1997) 2257-2263
4. Menschikowski M., Kasper M., Lattke P., Schiering A., Schiefer S., Stockinger H., and Jaross W. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 118 2 (1995) 173-181
5. Anthonsen M.W., Stengel D., Hourton D., Ninio E., and Johansen B. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 20 5 (2000) 1276-1282
6. Hurt-Camejo E., Andersen S., Standal R., Rosengren B., Sartipy P., Stadberg E., and Johansen B. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17 2 (1997) 300-309
7. Schiering A., Menschikowski M., Mueller E., and Jaross W. Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis 144 1 (1999) 73-78
8. Wooton-Kee C.R., Boyanovsky B.B., Nasser M.S., de Villiers W.J., and Webb N.R. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 24 4 (2004) 762-767
9. Hanasaki K., Yamada K., Yamamoto S., Ishimoto Y., Saiga A., Ono T., Ikeda M., Notoya M., Kamitani S., and Arita H. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277 32 (2002) 29116-29124
10. Romano M., Romano E., Bjorkerud S., and Hurt-Camejo E. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler. Thromb. Vasc. Biol. 18 4 (1998) 519-525
11. Sartipy P., Johansen B., Camejo G., Rosengren B., Bondjers G., and Hurt-Camejo E. Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity. J. Biol. Chem. 271 42 (1996) 26307-26314
12. Sartipy P., Johansen B., Gasvik K., and Hurt-Camejo E. Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions. Circ. Res. 86 6 (2000) 707-714
13. Sartipy P., Bondjers G., and Hurt-Camejo E. Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arterioscler. Thromb. Vasc. Biol. 18 12 (1998) 1934-1941
14. Eckey R., Menschikowski M., Lattke P., and Jaross W. Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2. Atherosclerosis 132 2 (1997) 165-176
15. Harduin P., Tailleux A., Lestavel S., Clavey V., Fruchart J.C., and Fievet C. Immunological and functional properties of in vitro oxidized low density lipoprotein. J. Lipid Res. 36 5 (1995) 919-930
16. Hakala J.K., Oorni K., Ala-Korpela M., and Kovanen P.T. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin. Arterioscler. Thromb. Vasc. Biol. 19 5 (1999) 1276-1283
17. Oorni K., Hakala J.K., Annila A., Ala-Korpela M., and Kovanen P.T. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273 44 (1998) 29127-29134
18. Hakala J.K., Oorni K., Pentikainen M.O., Hurt-Camejo E., and Kovanen P.T. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol. 21 6 (2001) 1053-1058
19. Aviram M., and Maor I. Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. Biochem. Biophys. Res. Commun. 185 1 (1992) 465-472
20. Sakai M., Miyazaki A., Hakamata H., Sato Y., Matsumura T., Kobori S., Shichiri M., and Horiuchi S. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 16 4 (1996) 600-605
21. Matsumura T., Sakai M., Kobori S., Biwa T., Takemura T., Matsuda H., Hakamata H., Horiuchi S., and Shichiri M. Two intracellular signaling pathways for activation of protein kinase C are involved in oxidized low-density lipoprotein-induced macrophage growth. Arterioscler. Thromb. Vasc. Biol. 17 11 (1997) 3013-3020
22. Terkeltaub R., Banka C.L., Solan J., Santoro D., Brand K., and Curtiss L.K. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler. Thromb. 14 1 (1994) 47-53
23. Li A., Dubey S., Varney M.L., Dave B.J., and Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170 6 (2003) 3369-3376
24. Oestvang J., Bonnefont-Rousselot D., Ninio E., Hakala J.K., Johansen B., and Anthonsen M.W. Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity. J. Lipid Res. 45 5 (2004) 831-838
25. Sakai M., Miyazaki A., Hakamata H., Sasaki T., Yui S., Yamazaki M., Shichiri M., and Horiuchi S. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J. Biol. Chem. 269 50 (1994) 31430-31435
26. Prokazova N.V., Zvezdina N.D., and Korotaeva A.A. Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry (Mosc.) 63 1 (1998) 31-37
27. Xu Y., Xiao Y.J., Zhu K., Baudhuin L.M., Lu J., Hong G., Kim K.S., Cristina K.L., Song L., Williams F.S., et al. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr. Drugs Targets, Immune Endocr. Metabol. Disord. 3 1 (2003) 23-32
28. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 85 8 (1988) 2805-2809
29. Ousman S.S., and David S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 30 1 (2000) 92-104
30. Yang L.V., Radu C.G., Wang L., Riedinger M., and Witte O.N. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 105 3 (2005) 1127-1134
31. Parks B.W., Gambill G.P., Lusis A.J., and Kabarowski J.H. Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice. J. Lipid Res. 46 7 (2005) 1405-1415
32. Murakami N., Yokomizo T., Okuno T., and Shimizu T. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J. Biol. Chem. 279 41 (2004) 42484-42491
33. Obinata H., Hattori T., Nakane S., Tatei K., and Izumi T. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J. Biol. Chem. 280 49 (2005) 40676-40683
34. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., and Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293 5530 (2001) 702-705
35. Weber C., Erl W., and Weber P.C. Enhancement of monocyte adhesion to endothelial cells by oxidatively modified low-density lipoprotein is mediated by activation of CD11b. Biochem. Biophys. Res. Commun. 206 2 (1995) 621-628
36. Oka H., Kugiyama K., Doi H., Matsumura T., Shibata H., Miles L.A., Sugiyama S., and Yasue H. Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arterioscler. Thromb. Vasc. Biol. 20 1 (2000) 244-250
37. Ramos M.A., Kuzuya M., Esaki T., Miura S., Satake S., Asai T., Kanda S., Hayashi T., and Iguchi A. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 18 7 (1998) 1188-1196
38. Nakano T., Raines E.W., Abraham J.A., Klagsbrun M., and Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc. Natl. Acad. Sci. U. S. A. 91 3 (1994) 1069-1073
39. Ouchi N., Kihara S., Yamashita S., Higashiyama S., Nakagawa T., Shimomura I., Funahashi T., Kameda-Takemura K., Kawata S., Taniguchi N., et al. Role of membrane-anchored heparin-binding epidermal growth factor-like growth factor and CD9 on macrophages. Biochem. J. 328 Pt 3 (1997) 923-928
40. Chisolm III G.M., and Chai Y. Regulation of cell growth by oxidized LDL. Free Radic. Biol. Med. 28 12 (2000) 1697-1707
41. Oestvang J., Anthonsen M.W., and Johansen B. Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release. FEBS Lett. 555 2 (2003) 257-262
42. Gomez-Munoz A., O'Brien L., Hundal R., and Steinbrecher U.P. Lysophosphatidylcholine stimulates phospholipase D activity in mouse peritoneal macrophages. J. Lipid Res. 40 6 (1999) 988-993
43. Gomez-Munoz A., Martens J.S., and Steinbrecher U.P. Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages. Arterioscler. Thromb. Vasc. Biol. 20 1 (2000) 135-143
44. Liu-Wu Y., Hurt-Camejo E., and Wiklund O. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis 137 2 (1998) 351-357
45. Perrin-Cocon L., Agaugue S., Coutant F., Saint-Mezard P., Guironnet-Paquet A., Nicolas J.F., Andre P., and Lotteau V. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine 24 9 (2006) 1254-1263
46. Yuan Y., Schoenwaelder S.M., Salem H.H., and Jackson S.P. The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase. J. Biol. Chem. 271 43 (1996) 27090-27098
47. Jing Q., Xin S.M., Zhang W.B., Wang P., Qin Y.W., and Pei G. Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ. Res. 87 1 (2000) 52-59
48. Ogita T., Tanaka Y., Nakaoka T., Matsuoka R., Kira Y., Nakamura M., Shimizu T., and Fujita T. Lysophosphatidylcholine transduces Ca2+ signaling via the platelet-activating factor receptor in macrophages. Am. J. Physiol. 272 1 Pt. 2 (1997) H17-H24
49. Yun M.R., Okajima F., and Im D.S. The action mode of lysophosphatidylcholine in human monocytes. J. Pharmacol. Sci. 94 1 (2004) 45-50
50. Zhang W.Y., Schwartz E., Wang Y., Attrep J., Li Z., and Reaven P. Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26 3 (2006) 514-519
51. Lee J.Y., Sohn K.H., Rhee S.H., and Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276 20 (2001) 16683-16689
52. Suganami T., Nishida J., and Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 25 10 (2005) 2062-2068
53. Tripathy D., Mohanty P., Dhindsa S., Syed T., Ghanim H., Aljada A., and Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52 12 (2003) 2882-2887
54. Bahramian N., Ostergren-Lunden G., Bondjers G., and Olsson U. Fatty acids induce increased granulocyte macrophage-colony stimulating factor secretion through protein kinase C-activation in THP-1 macrophages. Lipids 39 3 (2004) 243-249
55. Svensson L., Camejo G., Cabre A., Vallve J.C., Pedreno J., Noren K., Wiklund O., and Hulten L.M. Fatty acids modulate the effect of darglitazone on macrophage CD36 expression. Eur. J. Clin. Investig. 33 6 (2003) 464-471
56. Jostarndt K., Rubic T., Kuhn H., Anthosen M.W., Andera L., Gellert N., Trottman M., Weber C., Johansen B., Hrboticky N., et al. Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way. Biochem. Pharmacol. 67 5 (2004) 841-854
57. Jostarndt K., Gellert N., Rubic T., Weber C., Kuhn H., Johansen B., Hrboticky N., and Neuzil J. Dissociation of apoptosis induction and CD36 upregulation by enzymatically modified low-density lipoprotein in monocytic cells. Biochem. Biophys. Res. Commun. 290 3 (2002) 988-993
58. Rumsey S.C., Galeano N.F., Lipschitz B., and Deckelbaum R.J. Oleate and other long chain fatty acids stimulate low density lipoprotein receptor activity by enhancing acyl coenzyme A: cholesterol acyltransferase activity and altering intracellular regulatory cholesterol pools in cultured cells. J. Biol. Chem. 270 17 (1995) 10008-10016
59. Katsuda S., and Kaji T. Atherosclerosis and extracellular matrix. J. Atheroscler. Thromb. 10 5 (2003) 267-274
60. Heeneman S., Cleutjens J.P., Faber B.C., Creemers E.E., van Suylen R.J., Lutgens E., Cleutjens K.B., and Daemen M.J. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J. Pathol. 200 4 (2003) 516-525
61. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 9 (2002) 1135-1143
62. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 2 (1999) 115-126
63. Virmani R., Kolodgie F.D., Burke A.P., Farb A., and Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20 5 (2000) 1262-1275
64. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull Jr. W., Rosenfeld M.E., Schwartz C.J., Wagner W.D., and Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15 9 (1995) 1512-1531
65. Ivandic B., Castellani L.W., Wang X.P., Qiao J.H., Mehrabian M., Navab M., Fogelman A.M., Grass D.S., Swanson M.E., de Beer M.C., et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19 5 (1999) 1284-1290
66. Ghesquiere S.A., Gijbels M.J., Anthonsen M., van Gorp P.J., van der Made I., Johansen B., Hofker M.H., and de Winther M.P. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J. Lipid Res. 46 2 (2005) 201-210
67. Nagase T., Uozumi N., Ishii S., Kita Y., Yamamoto H., Ohga E., Ouchi Y., and Shimizu T. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat. Med. 8 5 (2002) 480-484
68. Ghosh M., Stewart A., Tucker D.E., Bonventre J.V., Murphy R.C., and Leslie C.C. Role of cytosolic phospholipase A(2) in prostaglandin E(2) production by lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 30 1 (2004) 91-100